| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC35B1 |
| Uniprot No | P78383 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-322 aa |
| 活性数据 | MASSSSLVPDRLRLPLCFLGVFVCYFYYGILQEKITRGKYGEGAKQETFTFALTLVFIQCVINAVFAKILIQFFDTARVDRTRSWLYAACSISYLGAMVSSNSALQFVNYPTQVLGKSCKPIPVMLLGVTLLKKKYPLAKYLCVLLIVAGVALFMYKPKKVVGIEEHTVGYGELLLLLSLTLDGLTGVSQDHMRAHYQTGSNHMMLNINLWSTLLLGMGILFTGELWEFLSFAERYPAIIYNILLFGLTSALGQSFIFMTVVYFGPLTCSIITTTRKFFTILASVILFANPISPMQWVGTVLVFLGLGLDAKFGKGAKKTSH |
| 分子量 | 62.2 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SLC35B1蛋白的3-4篇假设性文献示例，基于该蛋白已知功能的研究方向(实际文献需通过学术数据库验证)：
---
1. **文献名称**: "SLC35B1 regulates nucleotide sugar transport and promotes colorectal cancer metastasis"
**作者**: Zhang, Y., et al.
**摘要**: 研究揭示了SLC35B1通过调控高尔基体核苷酸糖转运，影响结直肠癌细胞表面蛋白糖基化，进而激活TGF-β信号通路并促进肿瘤转移。
2. **文献名称**: "SLC35B1 deficiency impairs HER2 glycosylation and suppresses breast cancer progression"
**作者**: Wang, L., et al.
**摘要**: 本研究发现，SLC35B1缺失导致HER2受体糖基化异常，抑制其膜定位和下游信号传导，显著降低乳腺癌细胞增殖和体内成瘤能力，提示其作为治疗靶点的潜力。
3. **文献名称**: "Interaction between SLC35B1 and RNA-binding proteins in mRNA stability regulation"
**作者**: Li, X., et al.
**摘要**: 通过蛋白质组学分析，发现SLC35B1与多种RNA结合蛋白互作，可能通过调控特定mRNA(如炎症因子)的稳定性参与肿瘤微环境重塑。
4. **文献名称**: "SLC35B1 acts as a tumor suppressor in glioma by modulating STAT3 signaling"
**作者**: Chen, J., et al.
**摘要**: 该研究提出SLC35B1在胶质瘤中低表达与患者不良预后相关，其过表达可抑制STAT3磷酸化，减少肿瘤干细胞样特性，表明其具有抑癌功能。
---
**注意**：以上文献为假设性示例，真实研究需通过PubMed、Web of Science等平台检索关键词如“SLC35B1”、“solute carrier family 35”等获取。
Solute Carrier Family 35 Member B1 (SLC35B1) is a nucleotide sugar transporter belonging to the SLC35 subfamily, which plays a critical role in glycosylation processes. This protein is localized to the Golgi apparatus and endoplasmic reticulum, where it facilitates the transport of adenosine 3'-phospho-5'-phosphosulfate (PAPS), a key sulfate donor, into the lumen of these organelles. PAPS is essential for sulfation reactions mediated by sulfotransferases, which modify glycosaminoglycans, proteoglycans, hormones, and other biomolecules. Such post-translational modifications are vital for cellular functions, including extracellular matrix organization, cell signaling, and molecular recognition.
The recombinant human SLC35B1 protein is produced using biotechnological platforms (e.g., mammalian, insect, or bacterial expression systems) to study its structure, transport mechanisms, and interaction partners. Recombinant variants enable functional characterization, such as kinetics of substrate transport or the impact of mutations linked to diseases. Dysregulation of SLC35B1 has been implicated in skeletal dysplasia, impaired sulfation pathways, and cancer metastasis due to aberrant glycosylation. Research on recombinant SLC35B1 contributes to understanding congenital glycosylation disorders and developing therapeutic strategies targeting sulfation-dependent pathways. Its study also offers insights into broader cellular metabolism and membrane transport biology.
×
